Backed by €400 million (US$449 million) in EU-cleared German aid, the new Frankfurt facility is designed to secure insulin supply for people with diabetes from 2032.
|Articles|October 15, 2016
- BioPharm International-10-15-2016
- Volume 2016 eBook
- Issue 2
Evaluating Technology and Innovation in Biopharmaceutical Manufacturing
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
Advertisement
Manufacturing equipment, technologies, and processes need to constantly evolve. Technical personnel from Janssen Supply Chain (JSC) and consultants from KPMG's Global Strategy Group discuss a technology management process to identify and evaluate new technologies in biopharmaceutical manufacturing to aid business decisions and improve supply chain capabilities.
Articles in this issue
about 10 years ago
Cell Line Quality Technologiesabout 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Data Integrity Challenges in Manufacturingabout 10 years ago
Seeking Accelerated Biosimilar Characterizationabout 10 years ago
Plant-Made Pharmaceuticals—Accelerating Drug Development Globallyabout 10 years ago
Testing the BrothAdvertisement
Related to this article
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.
Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC.
Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial.
Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin.
Advertisement
Advertisement
Trending on BioPharm International
1
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
2
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
3
FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy
4
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
5